DNA Methylation and Vascular Function

RECRUITING

I'm interested ...!!

The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive/therapeutic interventions such as aerobic exercise.

Conditions:

🦠 Obesity 🦠 Vascular Dysfunction

🗓️ Study Start (Actual) 11 October 2019

🗓️ Primary Completion (Estimated) 30 June 2024

✅ Study Completion (Estimated) 31 August 2024

👥 Enrollment (Estimated) 80

🔬 Study Type INTERVENTIONAL

📊 Phase NA

Locations:

📍 Chicago, Illinois, United States

📋 Eligibility Criteria

Description

Inclusion Criteria:

* BMI ≥ 35 kg/m2
* Between ages 18-50 years
* Not pregnant
* Approved for a bariatric surgery

Exclusion Criteria:

* To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded
* Pregnant women will be excluded, as they will not be eligible for bariatric surgery
* Current smokers
* Currently abusing alcohol or drugs

Ages Eligible for Study: 18 Years to 50 Years (ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 3 May 2018
First Submitted that Met QC Criteria 15 May 2018
First Posted 17 May 2018

Study Record Updates

Last Update Submitted that Met QC Criteria 28 June 2024
Last Update Posted 1 July 2024
Last Verified June 2024